查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1916947

SGLT2抑制劑治療市場按產品類型、適應症、規格、通路和最終用戶分類－全球預測（2026-2032年）

SGLT2 Inhibitors Treatment Market by Product Type, Indication, Strength, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

SGLT2抑制劑治療市場預計到2025年將達到176.5億美元，到2026年將成長到189.6億美元，到2032年將達到323.5億美元，年複合成長率為9.03%。

主要市場統計數據
基準年 2025 176.5億美元
預計年份：2026年 189.6億美元
預測年份：2032年 323.5億美元
複合年成長率 (%) 9.03%

權威解讀SGLT2抑制劑療法：整合臨床進展、跨專科應用、治療管道以及對相關人員的策略意義

SGLT2抑制劑已從最初局限於降血糖的藥物發展成為影響心血管代謝和腎臟疾病整體的多效療法。本文概述了這些藥物的治療、臨床和商業性背景，整合了最新的臨床證據、指南更新以及影響處方和用藥的醫療服務模式變革。說明將重點介紹其除血糖控制之外的其他作用機制，並探討這些益處如何重塑臨床應用、藥物推廣和相關人員的期望。

全面探討不斷擴大的證據、不斷發展的指南以及醫療保健服務領域的創新如何從根本上重塑SGLT2抑制劑的採用和獲取。

由於臨床證據、指引更新和創新醫療模式的融合，SGLT2抑制劑的治療格局正在經歷變革性變化。過去幾年，隨機試驗和真實世界數據分析拓展了這類藥物的適應症，指南專家小組也提供了全面的建議，認可了它們在血糖控制之外，對心臟衰竭和腎臟保護的益處。因此，治療策略正從以糖尿病為中心的方法轉變為整合心血管代謝和腎功能的綜合策略。

對2025年關稅調整對SGLT2治療藥物供應鏈決策、採購經濟效益與合約策略的影響進行務實分析

預計2025年貿易政策調整和關稅波動將為SGLT2抑制劑分銷和採購相關相關人員帶來更多複雜性。進口關稅和供應鏈相關課稅的變化可能會影響成品藥和活性藥物成分的到岸成本，促使經銷商和醫療保健系統重新評估合約策略、定價模式和庫存計劃。其影響不僅限於單位成本，還會影響跨境採購決策以及擁有不同生產基地的製造商之間的競爭。

將分子特異性特徵、治療適應症、分銷管道、終端用戶環境和劑量強度與差異化的臨床和商業性需求聯繫起來的詳細細分分析

本文建構了一個針對SGLT2抑制劑的詳細細分框架，重點分析了臨床效益、用藥障礙和商業性機會之間的交集。按產品類型分類，該治療領域包含不同的分子——Canagliflozin、Dapagliflozin、恩格Empagliflozin和艾格列淨——每種分子都有其特定的循證依據、安全性特徵和品牌歷史，這些因素會影響配藥師的選擇以及藥物在藥品目錄中的排名。依適應症檢驗趨勢發現，慢性腎臟病、心臟衰竭和第2型糖尿病的需求模式各不相同。在這些領域內，實證醫學證據的強度和指南推薦決定了專科醫生和全科醫生採用該藥物的優先順序。

策略性區域觀點揭示了美洲、歐洲、中東和非洲以及亞太地區的醫療保健生態系統如何以不同的方式推動SGLT2抑制劑療法的採用、取得和報銷趨勢。

區域差異影響SGLT2抑制劑計畫的臨床應用模式、報銷架構和策略重點。美洲地區的醫療保健體係由公私混合支付，深受管理式醫療處方箋以及以結果為導向、以以金額為準的心臟衰竭和腎臟病預防合約試點計畫的影響。這種環境鼓勵強力的衛生經濟學證據和以支付觀點的價值提案，區域卓越中心主導SGLT2抑制劑的應用，並將指南轉化為實踐。

重點評估競爭定位、策略聯盟和基於證據的差異化策略，這些策略將決定SGLT2抑制劑贊助商的商業性成功。

創新品牌與新進者之間的競爭體現在臨床差異化、實證投入以及與整個醫療生態系統的策略夥伴關係。領先的專有分子憑藉可靠的心血管和腎臟療效數據、已獲得的臨床醫生認可以及廣泛的藥品目錄覆蓋，繼續在各個細分市場佔據主導地位。同時，處於研發管線的參與企業和後期製劑正透過專注於拓展適應症、提升安全性或開發新型給藥方式，開闢獨特的臨床市場。

為行業領導者提供切實可行的高影響力建議，以整合臨床證據、支付方參與、分銷韌性和跨部門商業化，從而實現永續的醫療服務可及性。

產業領導者應採取多管齊下的方法，整合證據產生、相關人員和營運準備，以加速推廣應用並實現永續的醫療服務取得。首先，應優先進行跨適應症的證據項目，這些項目應涵蓋心臟病學和腎臟病學終點以及血糖控制結果，從而產生支付方和專科醫學協會擴展指南所需的數據。其次，應投資於支付方價值評估文件和真實世界結果研究，以量化風險分擔機制相關事件的臨床意義顯著的減少。

我們採用透明、三角驗證的調查方法，結合臨床文獻、指引分析、相關人員訪談和情境測試，以得出可操作的實證結論。

本分析的調查方法採用三角測量法，整合了同儕審查的臨床文獻、指南聲明、支付方政策文件以及利害關係人的定性回饋。主要研究包括對循環系統、腎臟病學和基層醫療領域的臨床醫生，以及醫院藥屋主任和專科藥房負責人進行結構化訪談，以了解實際治療啟動途徑、依從性障礙和處方集決策標準。這些發現得到了利用臨床日記、安全資訊和專業學會文件的二次研究的支持。

一份簡明扼要的綜合報告，清楚闡述了臨床擴展、准入需求、SGLT2抑制劑應用以及營運重點等因素對患者持續獲益的策略影響。

總之，SGLT2抑制劑代表了一種變革時期的治療藥物類別，其作用已從血糖控制擴展到更廣泛的實證心血管和腎臟疾病治療。隨著這一發展進程的不斷推進，相關人員需要調整其臨床管道、支付方價值提案和營運策略，以反映多學科影響和不斷變化的醫療服務獲取環境。展望未來，臨床應用將越來越依賴可靠的真實世界數據、與之相符的支付方價值提案以及支持治療啟動、後續觀察和患者依從性的整合式醫療模式。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. SGLT2抑制劑治療市場（依產品類型分類）

  • Canagliflozin
  • Dapagliflozin
  • Empagliflozin
  • 艾格列淨

9. SGLT2抑制劑治療市場（依適應症分類）

  • 慢性腎臟病
  • 心臟衰竭
  • 2型糖尿病

10. SGLT2抑制劑治療市場（依強度分類）

  • 10mg
  • 25mg

11. SGLT2抑制劑治療市場依分銷管道分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

12. SGLT2抑制劑治療市場（依最終用戶分類）

  • 診所
  • 居家護理患者
  • 醫院

13. SGLT2抑制劑治療市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 SGLT2抑制劑治療市場（按組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 各國SGLT2抑制劑治療市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章美國SGLT2抑制劑治療市場

第17章：中國SGLT2抑制劑治療市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AstraZeneca PLC
  • Boehringer Ingelheim International GmbH
  • Cipla Limited
  • Dr. Reddy's Laboratories Limited
  • Eli Lilly and Company
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Mylan NV
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd
Product Code: MRR-AE420CB15411

The SGLT2 Inhibitors Treatment Market was valued at USD 17.65 billion in 2025 and is projected to grow to USD 18.96 billion in 2026, with a CAGR of 9.03%, reaching USD 32.35 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 17.65 billion
Estimated Year [2026] USD 18.96 billion
Forecast Year [2032] USD 32.35 billion
CAGR (%) 9.03%

An authoritative orientation to SGLT2 inhibitor therapeutics synthesizing clinical evolution, cross-specialty adoption, and the strategic implications for care pathways and stakeholders

SGLT2 inhibitors have transitioned from a narrowly defined glucose-lowering option to a multifaceted therapeutic class with implications across cardiometabolic and renal care. This introduction frames the therapeutic, clinical, and commercial context for these agents by synthesizing recent clinical evidence, guideline evolution, and care delivery changes that influence prescribing and access. The narrative that follows emphasizes the mechanism-driven benefits that extend beyond glycemic control and discusses how those benefits are reshaping clinical pathways, formulary conversations, and stakeholder expectations.

Importantly, the introduction positions SGLT2 inhibitors as interventions whose value proposition is being continuously refined through post-approval data and health-system implementation efforts. It highlights how cardiology, nephrology, and primary care adoption trajectories are being influenced by new endpoints, safety data, and payer criteria. In doing so, readers will gain a compact but deep orientation to the therapeutic class, the principal drivers that are altering utilization patterns, and the strategic considerations that organizations must address to maintain competitiveness and clinical relevance.

A comprehensive exploration of how evidence expansion, guideline evolution, and care delivery innovation are fundamentally reshaping SGLT2 inhibitor adoption and access

The landscape for SGLT2 inhibitor treatment is undergoing transformative shifts driven by convergence of clinical evidence, guideline updates, and care model innovations. Over the past several years, randomized trials and real-world analyses have broadened the indications for the class, prompting guideline committees to issue more inclusive recommendations that recognize benefits in heart failure and renal protection in addition to glycemic control. Consequently, therapeutic positioning is evolving from a diabetes-centered approach to an integrated cardiometabolic and renal strategy.

Concurrently, payers and health systems are modifying coverage frameworks to reflect outcomes-based value, which has accelerated adoption in specialty clinics and multidisciplinary programs. Pharmacoeconomic analyses and value dossiers are now essential components of market access strategies, and manufacturers are adapting their evidence-generation plans to support these narratives. In parallel, clinical practice is shifting toward earlier combination therapy and cross-specialty prescribing, with cardiologists and nephrologists increasingly initiating SGLT2 inhibitors independently of endocrinologists.

Moreover, advances in digital health and remote monitoring are altering adherence support and patient selection, enabling clinicians to identify candidates with high incremental benefit and to follow safety parameters more closely. As a result, commercial teams must realign segmentation, messaging, and clinical engagement to reflect a more heterogeneous prescriber base and to support multidisciplinary pathways. Taken together, these trends represent a structural change in how the class is perceived, adopted, and reimbursed across care settings, creating new windows for differentiation and partnership across the value chain.

A pragmatic analysis of how adjustments to United States tariff policy in 2025 could influence supply chain decisions, procurement economics, and contractual strategies for SGLT2 treatments

Anticipated trade policy adjustments and tariff shifts in the United States for 2025 introduce another layer of complexity for stakeholders involved in SGLT2 inhibitor distribution and procurement. Changes in import duties and supply-chain levies can affect the landed cost of finished formulations and active pharmaceutical ingredients, which in turn may prompt revisions to contracting strategies, pricing models, and inventory planning across distributors and health systems. The implications extend beyond unit costs to encompass cross-border sourcing decisions and the relative competitiveness of manufacturers with different production footprints.

Supply chain resilience therefore becomes a strategic priority, with organizations evaluating nearshoring, multiple-sourcing, and inventory buffering as mitigations against tariff-driven cost volatility. Payers and integrated delivery networks may respond by tightening formulary controls or by negotiating longer-term agreements that buffer against abrupt price movements. At the same time, manufacturers with diversified manufacturing and distribution capabilities will be better positioned to absorb incremental tariff effects or to re-route logistics to preserve price competitiveness.

Clinicians and procurement leaders should anticipate that procurement cycles may incorporate greater sensitivity to total cost of ownership considerations, including tariff exposure, freight variability, and storage requirements. Consequently, commercial teams need to prepare scenario-based contracting templates and to quantify the operational impact of tariff permutations on supply continuity and gross-to-net economics. In short, tariff dynamics are likely to influence commercial levers and operational decisions across the SGLT2 ecosystem, reinforcing the need for proactive risk management and cross-functional alignment.

In-depth segmentation insights tying molecule-specific profiles, therapeutic indications, distribution channels, end-user settings, and dose strength to differentiated clinical and commercial imperatives

A granular segmentation framework clarifies where clinical benefit, access friction, and commercial opportunity intersect for SGLT2 inhibitors. Based on product type, the therapeutic landscape is characterized by distinct molecules such as Canagliflozin, Dapagliflozin, Empagliflozin, and Ertugliflozin, each of which has specific evidence bases, safety profiles, and brand histories that influence prescriber preference and formulary positioning. Examining indication-driven dynamics reveals differentiated demand patterns across Chronic Kidney Disease, Heart Failure, and Type 2 Diabetes, where evidence strength and guideline endorsements determine the priority of uptake within specialist groups and general practice.

Distribution channel considerations matter significantly for patient access and adherence, with hospital pharmacies often acting as points of initiation for in-hospital starts, online pharmacies providing convenience and continuity for maintenance therapy, and retail pharmacies serving as the predominant refilling touchpoint and a locus for patient counseling. End-user segmentation further sharpens operational and messaging requirements: clinics require streamlined initiation pathways and clinical decision support; homecare patients need clear remote-monitoring protocols and adherence interventions; and hospitals demand alignment with inpatient formularies and discharge planning processes. Strength differentiation, specifically 10 mg and 25 mg formulations, influences prescribing patterns based on renal function considerations, titration strategies, and co-prescribing with other cardiometabolic agents.

Integrating these segmentation lenses enables a more precise understanding of where to prioritize evidence generation, commercial resource allocation, and clinical outreach. It also highlights the need for tailored messaging that addresses the unique decision drivers of each prescriber type, distribution partner, and patient cohort, supporting interventions that improve initiation, persistence, and outcomes across the continuum of care.

Strategic regional perspectives articulating how Americas, Europe Middle East & Africa, and Asia-Pacific healthcare ecosystems drive distinct adoption, access, and reimbursement dynamics for SGLT2 therapies

Regional heterogeneity shapes clinical adoption patterns, reimbursement frameworks, and strategic priorities for SGLT2 inhibitor programs. In the Americas, care delivery is characterized by a mix of private and public payers, with strong influence from managed-care formularies and value-based contracting pilots that emphasize outcomes in heart failure and renal disease prevention. This environment incentivizes robust health-economic evidence and payer-focused value narratives, while regional centers of excellence lead adoption and guideline translation into practice.

Across Europe, the Middle East & Africa, regulatory and reimbursement landscapes vary widely, with national health technology assessment bodies and regional procurement consortia playing decisive roles. In these settings, early generation cost-effectiveness studies and real-world evidence demonstrating renal and cardiovascular benefits are critical for securing favorable coverage and inclusion on national formularies. Meanwhile, some markets in the region are showing accelerated adoption through specialist networks and integrated care pathways that prioritize the prevention of hospitalizations and progression to end-stage organ disease.

The Asia-Pacific region presents a mosaic of healthcare systems, ranging from high-resource markets with established specialist engagement to emerging markets where access and affordability remain central constraints. In this region, local clinical guideline adaptation, pricing policies, and availability of biosimilar-like alternatives or locally produced generics will influence the pace and pattern of uptake. Across all regions, cross-border evidence-sharing, multinational payer pilots, and collaborative care models serve as accelerants for broader adoption, but localized strategies remain essential to navigate varying clinical priorities and reimbursement mechanisms.

A focused evaluation of competitive positioning, strategic alliances, and evidence-driven differentiation tactics that determine commercial success for SGLT2 inhibitor sponsors

Competitive dynamics among originator brands and newer entrants are defined by clinical differentiation, evidence investment, and strategic partnerships across the healthcare ecosystem. Leading proprietary molecules retain advantages where robust cardiovascular and renal outcome data exist alongside established clinician familiarity and broad formulary presence. Meanwhile, pipeline entrants and later-stage formulations focus on indication expansion, improved safety signals, or novel delivery modalities to carve out distinct clinical niches.

Partnerships with specialty pharmacies, integrated delivery networks, and digital therapeutics vendors are increasingly common as companies seek to embed their therapies into care pathways and adherence programs. Additionally, strategic collaborations with academic centers and professional societies to sponsor guideline-driven research and real-world evidence studies help to accelerate acceptance among non-specialist prescribers. Manufacturers are also exploring innovative contracting approaches that tie reimbursement to clinical outcomes or episode-of-care metrics, thereby aligning commercial incentives with payer priorities.

For commercial teams, the competitive imperative is to translate clinical differentiation into accessible value propositions for payers and clinicians while ensuring operational excellence in supply, patient support, and educational outreach. Organizations that combine strong evidence planning with pragmatic channel strategies and partnerships will be best positioned to influence prescribing behavior and maintain resilient access across a shifting reimbursement landscape.

High-impact, actionable recommendations for industry leaders to align clinical evidence, payer engagement, distribution resilience, and cross-functional commercialization for durable access

Industry leaders should adopt a multi-dimensional approach that aligns evidence generation, stakeholder engagement, and operational readiness to accelerate adoption and enable sustainable access. First, prioritize cross-indication evidence programs that address cardiology and nephrology endpoints in addition to glycemic outcomes, thereby generating the data payers and specialty societies require for broader guideline inclusion. Second, invest in payer-facing value dossiers and real-world outcome studies that quantify reduction in clinically meaningful events relevant to risk-sharing arrangements.

Third, develop differentiated channel strategies that support initiation in hospitals and clinics, continuity through retail and online pharmacies, and adherence via homecare support programs. This requires coordinated investments in digital adherence tools, nurse-led initiation pathways, and education for non-endocrinology prescribers. Fourth, prepare for tariff and supply-chain variability by diversifying sourcing, negotiating flexible contracting clauses, and creating scenario-based contingency plans to ensure uninterrupted supply.

Fifth, establish collaborative partnerships with specialty societies, patient advocacy organizations, and care delivery innovators to co-create guideline implementation tools and patient identification algorithms. Finally, implement cross-functional commercialization teams that integrate medical affairs, market access, and field commercial units to respond rapidly to evolving evidence and payer decisions. By executing these actions in parallel, leaders can convert clinical advantage into durable access and improved patient outcomes.

A transparent and triangulated research methodology combining clinical literature, guideline analysis, stakeholder interviews, and scenario testing to produce actionable, evidence-based insights

The research methodology underpinning this analysis integrates a triangulated approach that synthesizes peer-reviewed clinical literature, guideline statements, payer policy documents, and qualitative stakeholder input. Primary research included structured interviews with clinicians across cardiology, nephrology, and primary care, as well as with hospital pharmacy directors and specialty pharmacy leaders to capture real-world initiation pathways, adherence barriers, and formulary decision criteria. These insights were corroborated with secondary research drawing on clinical trial publications, safety communications, and professional society materials.

Data synthesis emphasized thematic convergence and cross-validation across information sources to identify robust patterns in prescribing behavior, payer responses, and operational constraints. Scenario planning and sensitivity analyses were employed to test the resilience of strategic recommendations against plausible changes in trade policy, reimbursement rules, and supply-chain disruptions. Throughout the methodology, transparency was maintained around inclusion criteria, source provenance, and the limitations of available data, ensuring that conclusions are grounded in verifiable evidence and expert interpretation rather than extrapolative forecasting.

A concise synthesis articulating the strategic consequences of clinical expansion, access imperatives, and operational priorities shaping SGLT2 inhibitor adoption and sustained patient benefit

In conclusion, SGLT2 inhibitors represent a therapeutic class in transition: their role has expanded from glycemic management to a broader, evidence-based contribution to cardiovascular and renal care. This evolution demands that stakeholders recalibrate clinical pathways, payer value narratives, and operational strategies to reflect the multi-specialty nature of benefit and the shifting landscape of access. Clinical adoption will increasingly depend on robust real-world evidence, payer-aligned value propositions, and integrated care models that support initiation, monitoring, and persistence.

Operationally, supply-chain resilience and proactive contracting will be necessary to manage external pressures such as tariff changes and logistical disruption. Commercial success will hinge on the ability to translate differentiated clinical evidence into tailored value stories for distinct prescriber groups and distribution channels, while maintaining alignment with payer expectations for outcomes and cost-effectiveness. By synthesizing clinical insight with pragmatic commercial planning, stakeholders can accelerate meaningful patient access and improve outcomes across diverse care settings.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. SGLT2 Inhibitors Treatment Market, by Product Type

  • 8.1. Canagliflozin
  • 8.2. Dapagliflozin
  • 8.3. Empagliflozin
  • 8.4. Ertugliflozin

9. SGLT2 Inhibitors Treatment Market, by Indication

  • 9.1. Chronic Kidney Disease
  • 9.2. Heart Failure
  • 9.3. Type 2 Diabetes

10. SGLT2 Inhibitors Treatment Market, by Strength

  • 10.1. 10 mg
  • 10.2. 25 mg

11. SGLT2 Inhibitors Treatment Market, by Distribution Channel

  • 11.1. Hospital Pharmacies
  • 11.2. Online Pharmacies
  • 11.3. Retail Pharmacies

12. SGLT2 Inhibitors Treatment Market, by End User

  • 12.1. Clinics
  • 12.2. Homecare Patients
  • 12.3. Hospitals

13. SGLT2 Inhibitors Treatment Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. SGLT2 Inhibitors Treatment Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. SGLT2 Inhibitors Treatment Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States SGLT2 Inhibitors Treatment Market

17. China SGLT2 Inhibitors Treatment Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AstraZeneca PLC
  • 18.6. Boehringer Ingelheim International GmbH
  • 18.7. Cipla Limited
  • 18.8. Dr. Reddy's Laboratories Limited
  • 18.9. Eli Lilly and Company
  • 18.10. Johnson & Johnson
  • 18.11. Merck & Co., Inc.
  • 18.12. Mylan N.V.
  • 18.13. Pfizer Inc.
  • 18.14. Sun Pharmaceutical Industries Ltd.
  • 18.15. Teva Pharmaceutical Industries Ltd

LIST OF FIGURES

  • FIGURE 1. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY STRENGTH, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES SGLT2 INHIBITORS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA SGLT2 INHIBITORS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY CANAGLIFLOZIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY CANAGLIFLOZIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY CANAGLIFLOZIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY DAPAGLIFLOZIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY DAPAGLIFLOZIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY DAPAGLIFLOZIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY EMPAGLIFLOZIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY EMPAGLIFLOZIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY EMPAGLIFLOZIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY ERTUGLIFLOZIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY ERTUGLIFLOZIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY ERTUGLIFLOZIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY CHRONIC KIDNEY DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY CHRONIC KIDNEY DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY CHRONIC KIDNEY DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY HEART FAILURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY HEART FAILURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY HEART FAILURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY TYPE 2 DIABETES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY TYPE 2 DIABETES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY TYPE 2 DIABETES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY 10 MG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY 10 MG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY 10 MG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY 25 MG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY 25 MG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY 25 MG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY HOMECARE PATIENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY HOMECARE PATIENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY HOMECARE PATIENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. AMERICAS SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 54. AMERICAS SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 55. AMERICAS SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 56. AMERICAS SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 57. AMERICAS SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 58. AMERICAS SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 59. NORTH AMERICA SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. NORTH AMERICA SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 61. NORTH AMERICA SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 62. NORTH AMERICA SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 63. NORTH AMERICA SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 64. NORTH AMERICA SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 65. LATIN AMERICA SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. LATIN AMERICA SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. LATIN AMERICA SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 68. LATIN AMERICA SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 69. LATIN AMERICA SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 70. LATIN AMERICA SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 71. EUROPE, MIDDLE EAST & AFRICA SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE, MIDDLE EAST & AFRICA SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE, MIDDLE EAST & AFRICA SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE, MIDDLE EAST & AFRICA SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE, MIDDLE EAST & AFRICA SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. MIDDLE EAST SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. MIDDLE EAST SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. MIDDLE EAST SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 86. MIDDLE EAST SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 87. MIDDLE EAST SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 88. MIDDLE EAST SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. AFRICA SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. AFRICA SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. AFRICA SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 92. AFRICA SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 93. AFRICA SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 94. AFRICA SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. ASEAN SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. ASEAN SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. ASEAN SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 105. ASEAN SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 106. ASEAN SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 107. ASEAN SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 108. GCC SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GCC SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. GCC SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 111. GCC SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 112. GCC SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 113. GCC SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPEAN UNION SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPEAN UNION SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPEAN UNION SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPEAN UNION SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPEAN UNION SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPEAN UNION SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. BRICS SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. BRICS SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. BRICS SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 123. BRICS SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 124. BRICS SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 125. BRICS SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. G7 SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. G7 SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. G7 SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 129. G7 SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 130. G7 SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 131. G7 SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. NATO SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. NATO SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. NATO SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 135. NATO SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 136. NATO SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 137. NATO SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. UNITED STATES SGLT2 INHIBITORS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 140. UNITED STATES SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. UNITED STATES SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 142. UNITED STATES SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 143. UNITED STATES SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 144. UNITED STATES SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. CHINA SGLT2 INHIBITORS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 146. CHINA SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. CHINA SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 148. CHINA SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 149. CHINA SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 150. CHINA SGLT2 INHIBITORS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)